Command Palette

Search for a command to run...

Vivo Bio Tech Ltd.
39.1(+0.26%)
1W: +3.20%

Peers

Snapshot Summary

Vivo Bio Tech Ltd. is significantly lagging behind its peers in terms of growth, profitability, and efficiency metrics. With a negative revenue growth rate and lower return ratios, it presents a challenging outlook compared to stronger competitors in the pharmaceuticals sector.

  • • Vivo Bio Tech Ltd. has negative revenue growth and EPS decline over the past three years.
  • • High debt-to-equity ratio (1.35) indicates potential financial risk.
  • • Sun Pharmaceutical Industries and Cipla Ltd. stand out as top performers in profitability metrics.
  • • Cipla Ltd.: Strong revenue growth (13.28% YoY) and high ROE (16.63%) with low debt (0.0093).
  • • Sun Pharmaceutical Industries Ltd.: Solid revenue growth (8.42% YoY), high ROE (16.13%), and almost negligible debt (0.0447).
  • • Dr. Reddy's Laboratories Ltd.: Impressive growth in EPS (68.07) and high ROE (21.76%) alongside low valuation metrics.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
Vivo Bio Tech Ltd.₹37.32₹79.62Cr9.869.97%1.35
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02
Explore
Watchlists
Chat
Portfolio